Deutsche Bank AG Purchases New Shares in Celcuity, Inc. $CELC

Deutsche Bank AG purchased a new position in Celcuity, Inc. (NASDAQ:CELC) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 39,622 shares of the company’s stock, valued at approximately $4,145,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of CELC. Parallel Advisors LLC acquired a new position in shares of Celcuity in the first quarter worth about $38,000. EverSource Wealth Advisors LLC raised its holdings in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Celcuity during the fourth quarter valued at approximately $42,000. PNC Financial Services Group Inc. lifted its position in shares of Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after acquiring an additional 86 shares in the last quarter. Finally, KBC Group NV purchased a new stake in shares of Celcuity in the 1st quarter valued at approximately $64,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Price Performance

NASDAQ CELC opened at $92.27 on Wednesday. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock has a market capitalization of $4.51 billion, a PE ratio of -21.46 and a beta of 0.20. Celcuity, Inc. has a 12-month low of $44.42 and a 12-month high of $151.02. The company has a 50 day moving average price of $94.38 and a two-hundred day moving average price of $107.44.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28). As a group, equities analysts predict that Celcuity, Inc. will post -4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CELC shares. Stifel Nicolaus decreased their price objective on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Citigroup restated a “market outperform” rating on shares of Celcuity in a report on Monday, August 17th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research report on Monday, August 17th. Needham & Company LLC lowered their price target on Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.